Oncozenge AB
OncoZenge AB (publ), a pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. It offers BupiZenge, which is in Phase 3 clinical trials for the treatment of pain in the oral cavity. The company was incorporated in 2020 and is headquartered in Bromma, Sweden.
Oncozenge AB (ONCOZ) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.377x
Based on the latest financial reports, Oncozenge AB (ONCOZ) has a cash flow conversion efficiency ratio of -0.377x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-3.51 Million) by net assets (Skr9.30 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Oncozenge AB - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Oncozenge AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Oncozenge AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oncozenge AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Spacetalk Ltd
AU:SPA
|
-0.153x |
|
Marquee Resources Ltd
AU:MQR
|
-0.132x |
|
Singularity Future Technology Ltd
NASDAQ:SGLY
|
-4.756x |
|
CONSTELLATION RES
F:0XX
|
N/A |
|
YPSOMED HLDG N
MU:OWX
|
N/A |
|
Rothwell International Co. Limited
KQ:900260
|
0.415x |
|
Cytophage Technologies Ltd.
V:CYTO
|
N/A |
|
NOST.TERRA OIL+G. LS-001
F:LMU1
|
N/A |
Annual Cash Flow Conversion Efficiency for Oncozenge AB (2020–2024)
The table below shows the annual cash flow conversion efficiency of Oncozenge AB from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr9.95 Million | Skr-8.76 Million | -0.881x | +3.89% |
| 2023-12-31 | Skr18.64 Million | Skr-17.08 Million | -0.916x | -41.02% |
| 2022-12-31 | Skr33.97 Million | Skr-22.08 Million | -0.650x | -995.02% |
| 2021-12-31 | Skr80.32 Million | Skr-4.77 Million | -0.059x | -173676.54% |
| 2020-12-31 | Skr29.28 Million | Skr-1.00K | 0.000x | -- |